BioCorRx Inc. (OTC: BICX)

BioCorRx Inc. operates in the healthcare industry, focusing on addiction treatment solutions and weight management programs. The company develops and provides unique approaches to treating substance use disorders and related conditions. Through its subsidiaries, BioCorRx offers a range of programs and products designed to address alcoholism, opioid addiction, and weight loss management. The company's primary focus is on developing innovative solutions that combine medication-assisted treatment with behavioral therapy and support services.

BioCorRx generates revenue through its proprietary programs and products, including the BioCorRx Recovery Program, the Beat Addiction Recovery Program, and the UnCraveRx Weight Loss Program. These programs are offered to healthcare providers who determine their appropriateness for patients. The company also generates revenue through license and distribution agreements with third parties for the establishment of addiction treatment centers and programs. Additionally, BioCorRx is involved in the development of pharmaceutical products, such as BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders, which is being developed with the goal of seeking U.S. Food and Drug Administration (FDA) approval.

• BioCorRx Recovery Program: This program focuses on alcoholism and opioid addiction treatment, utilizing a combination of medication and behavioral therapy. The program includes proprietary Cognitive Behavioral Therapy (CBT) modules and peer support via a mobile app, along with medication prescribed by independent treating physicians.

• Beat Addiction Recovery Program: This substance use disorder recovery program typically includes BioCorRx's proprietary CBT modules and peer support via mobile app, along with medication prescribed by an independent treating physician. The program is designed to provide comprehensive support for individuals seeking to overcome addiction.

• UnCraveRx Weight Loss Program: This medication-assisted weight loss program includes access to concierge on-demand wellness specialists, such as nutritionists, fitness experts, and behavioral experts. The program aims to provide a holistic approach to weight management, combining medication with lifestyle support.

• Pharmaceutical Development: BioCorRx Pharmaceuticals Inc., a subsidiary of BioCorRx Inc., is focused on the development of BICX104, an implantable naltrexone pellet for the treatment of opioid use disorder (OUD) and other substance use disorders. The company is seeking FDA approval for this product, which is designed to improve patient compliance to naltrexone therapy compared to other marketed treatments.

BioCorRx operates in a competitive industry with several key players in the addiction treatment and weight management sectors. The company's competitive advantages include its unique combination of medication-assisted treatment and behavioral therapy, as well as its focus on developing innovative solutions tailored to individual patient needs. BioCorRx's proprietary programs and products differentiate it from competitors, allowing it to carve out a niche in the market. The company's ongoing research and development efforts, particularly in the pharmaceutical sector, position it for potential growth and expansion in the future.

BioCorRx serves a broad customer base, including healthcare providers who utilize its programs and products for their patients. The company's programs are designed to be flexible and adaptable, catering to the specific needs of individual patients. By offering comprehensive support and innovative solutions, BioCorRx aims to make a meaningful impact on the lives of those struggling with addiction and weight management issues. The company's focus on evidence-based treatments and continuous improvement ensures that it remains at the forefront of the industry, providing high-quality care and support to its customers.